David Deng

Corporate Officer/Principal at Verinata Health, Inc.

Consumer Services

Health Services

Health Technology

Profile

David Deng is currently working as the Director of Assay Development at Verinata Health, Inc. Previously, he worked as a Principal at Agilent Technologies, Inc. Dr. Deng holds a doctorate degree from McGill University and undergraduate, graduate, and doctorate degrees from Shanghai Jiao Tong University.

David Deng active positions

Companies	Position	Start
Verinata Health, Inc. Verinata Health, Inc. Medical/Nursing ServicesHealth Services Verinata Health, Inc. focuses on maternal and fetal health. It develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities. The firm's products include 'verifi' prenatal test, a non-invasive test that detects three primary aneuploidies for trisomies 21, 18 and 13 from a single maternal blood draw as early as 10 weeks and 'Monosomy X', a test for Turner syndrome. The company was founded by Michael D. Grisham and Richard P. Rava in 2001 and is headquartered in San Diego, CA.	Corporate Officer/Principal	2009-08-10

All active positions of David Deng

Former positions of David Deng

Companies	Position	End
AGILENT TECHNOLOGIES, INC.	Corporate Officer/Principal	-

See the detail of David Deng's experience

Training of David Deng

McGill University	Doctorate Degree
Shanghai Jiao Tong University	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of David Deng's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
AGILENT TECHNOLOGIES, INC.	Health Technology

Private companies	1
Verinata Health, Inc. Verinata Health, Inc. Medical/Nursing ServicesHealth Services Verinata Health, Inc. focuses on maternal and fetal health. It develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities. The firm's products include 'verifi' prenatal test, a non-invasive test that detects three primary aneuploidies for trisomies 21, 18 and 13 from a single maternal blood draw as early as 10 weeks and 'Monosomy X', a test for Turner syndrome. The company was founded by Michael D. Grisham and Richard P. Rava in 2001 and is headquartered in San Diego, CA.	Health Services